Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Amcenestrant-matching placebo|DRUG: SAR439859|DRUG: Palbociclib|DRUG: Letrozole|DRUG: Goserelin|DRUG: Letrozole-matching placebo
Sponsor: Sanofi